[HTML][HTML] Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma
MW Rohaan, TH Borch, JH Van Den Berg… - New England journal …, 2022 - Mass Medical Soc
Background Immune checkpoint inhibitors and targeted therapies have dramatically
improved outcomes in patients with advanced melanoma, but approximately half these …
improved outcomes in patients with advanced melanoma, but approximately half these …
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
MW Rohaan, TH Borch, JH van den Berg… - The New England …, 2022 - europepmc.org
Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes
in patients with advanced melanoma, but approximately half these patients will not have a …
in patients with advanced melanoma, but approximately half these patients will not have a …
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
MW Rohaan, TH Borch, JH van den Berg, Ö Met… - 2022 - pubmed.ncbi.nlm.nih.gov
Background Immune checkpoint inhibitors and targeted therapies have dramatically
improved outcomes in patients with advanced melanoma, but approximately half these …
improved outcomes in patients with advanced melanoma, but approximately half these …
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
MW Rohaan, TH Borch, JH van den Berg… - New England Journal …, 2022 - research.rug.nl
Background: Immune checkpoint inhibitors and targeted therapies have dramatically
improved outcomes in patients with advanced melanoma, but approximately half these …
improved outcomes in patients with advanced melanoma, but approximately half these …
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
MW Rohaan, TH Borch… - New England …, 2022 - cris.maastrichtuniversity.nl
Background Immune checkpoint inhibitors and targeted therapies have dramatically
improved outcomes in patients with advanced melanoma, but approximately half these …
improved outcomes in patients with advanced melanoma, but approximately half these …
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
MW Rohaan, TH Borch… - New England …, 2022 - scholarlypublications …
BACKGROUND Immune checkpoint inhibitors and targeted therapies have dramatically
improved outcomes in patients with advanced melanoma, but approximately half these …
improved outcomes in patients with advanced melanoma, but approximately half these …
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
MW Rohaan, TH Borch… - New England journal …, 2022 - research.utwente.nl
Background Immune checkpoint inhibitors and targeted therapies have dramatically
improved outcomes in patients with advanced melanoma, but approximately half these …
improved outcomes in patients with advanced melanoma, but approximately half these …
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
MW Rohaan, TH Borch… - The New England …, 2022 - research.regionh.dk
BACKGROUND: Immune checkpoint inhibitors and targeted therapies have dramatically
improved outcomes in patients with advanced melanoma, but approximately half these …
improved outcomes in patients with advanced melanoma, but approximately half these …
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
MW Rohaan, TH Borch… - New England …, 2022 - researchinformation.amsterdamumc …
Background Immune checkpoint inhibitors and targeted therapies have dramatically
improved outcomes in patients with advanced melanoma, but approximately half these …
improved outcomes in patients with advanced melanoma, but approximately half these …
[引用][C] Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
MW Rohaan, TH Borch, JH van den Berg, Ö Met… - 2022 - repository.ubn.ru.nl
BACKGROUND: Immune checkpoint inhibitors and targeted therapies have dramatically
improved outcomes in patients with advanced melanoma, but approximately half these …
improved outcomes in patients with advanced melanoma, but approximately half these …